tbuckley/cabot-search huggingface dataset:
Recurrences of colorectal cancer: time distribution and diagnostic sensitivity of serum CEA, TPA, CA19.9, CA72.4 tumour markers
Authors: A. Nicolini, P. Ferrari, L. Anselmi, M. R. Metelli, A. Carpi, R. Spisni, M. Conte, P. Berti, P. Miccoli
Journal: Journal of Clinical Oncology (2005)

3723 Background: Unlike long-term survival of colorectal cancer the time distribution of recurrences is not well known and no clear role of serum tumour markers to detect them has been defined. Methods: 173 operated colorectal cancer patients, prolongly followed-up with serial instrumental examinations and serum CEA,TPA,CA19.9,CA72.4 tumour markers, were retrospectively evaluated; 78 (46%) had relapsed, while the 95 others, all followed up longer than 48 months, did not. At the time of primary surgery 28 (36%) of the 78 relapsed patients, were metastatic (M1) and in the 50 (64%) remaining the mod. Duke’s stage was: B1 (2) (2.5%), B2 (21) (27%) and C2 (27) (35%). As to the 95 disease-free patients, 3 (3%) were metastatic, and in the 92 remaining the mod. Duke’s stage was: A (14), B1 (18), B2 (34), C1 (6) C2 (20); their mean follow up was 87 + 12 (74–99 range), 127 + 50 (48–210 range), 120 + 47 (49–222 range), 126 + 50 (48–236 range), 118 + 79 (51–237 range) and 124 + 57 months (52–200 range) respectively. Sensitivity of combined serum CEA, TPA, CA19.9 and CA72.4 was evaluated in 64 (82%) relapsed patients. Results: In 49 (98%) of the 50 post-operatively recurred patients, recurrence occurred within 46 months and the median time was: 38 (30–46 range), 16 (3–39 range) and 15 (2–41 range) months for B1, B2 and C2 stages respectively. In the last 1 (2%) patient, with C2 stage, recurrence occurred 105 months after primary surgery. So recurrences were 20 (40%), 18 (36%), 8 (16%) 3 (6%) and 1 (2%) during the first, second, third, fourth year after primary surgery and thereafter respectively. Sensitivity of CEA-TPA, CEA-TPA-CA19.9 and CEA-TPA-CA19.9-CA72.4 panels was 86%, 87.5% and 93% respectively and the mean lead time of the 3 panels from tumour marker increase to the first pathological instrumental sign ranged from 3.6 to 3.9 months (0–18 range). Conclusions: These data suggest: a) 4 years after primary surgery is a principal end-point for colorectal cancer recurrences; b) serum CEA-TPA-CA19.9-CA72.4 and alternately serum CEA-TPA are sensitive tumour marker panels to post-operatively early detect colorectal cancer recurrences. No significant financial relationships to disclose.
Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Authors: Guillermo Garcia-Manero, Ehab Atallah, Olatoyosi Odenike, Bruno C Medeiros, Jorge E. Cortes, Vanessa Esquibel, Steven Cha, Samer K Khaled
Journal: Blood (2014)
Diurnal Variation in the Susceptibility of Mouse Epidermis to Carcinogen and Its Relationship to DNA Synthesis2
Authors: J. V. Frei, A. C. Ritchie
Journal: JNCI Journal of the National Cancer Institute (1964)

When papillomas were induced in mouse skin by a single application of 7,12-dimethylbenz[a]anthracene, followed by repeated applications of croton oil, more papillomas appeared when the carcinogen was applied at 10 PM than when given at 10 AM. The average mitotic frequency in the epidermis was lower in the hours following 10 PM than in the hours following 10 AM. It is therefore considered improbable that the carcinogen acts on cells in mitosis. The frequency of epidermal cells synthesizing deoxyribonucleic acid (DNA) preparatory to mitosis was, in contrast, higher in the hours following 10 PM than in those following 10 AM. It is suggested that the carcinogen may act on cells synthesizing DNA.
Abstract MP031: Birth Weight, Genetic-Susceptibility and Adulthood Risk of Type 2 Diabetes
Authors: Yanping Li, Qibin Qi, Tsegaselassie Workalemahu, Frank B Hu, Lu Qi
Journal: Circulation (2012)

Background: Both stressful intrauterine milieus and genetic susceptibility have been linked to later life diabetes risk. The present study aims to examine the interaction between low birth weight, a surrogate measure of stressful intrauterine milieus, and genetic susceptibility in relation to risk of type 2 diabetes in adulthood. Methods: The analysis included two independent, nested case-control studies of in total 2591 cases of type 2 diabetes and 3052 healthy controls from prospective cohorts: the Nurses’ Health Study (NHS) and the Health Professionals Follow-up Study (HPFS). We developed 2 genotype scores using susceptibility loci recently identified through Genome Wide Association Studies: 1) an ‘obesity genotype score’ based on 32 BMI-predisposing single nucleotide polymorphisms (SNPs); and 2) a ‘diabetes genotype score’ based on 35 diabetes-predisposing SNPs. Results: Both the obesity genotype score and diabetes genotype score showed consistently significant association with risk of type 2 diabetes in NHS and HPFS ( P for trend &lt; 0.01). In the pooled sample of the two cohorts, we found significant interaction between birth weight and obesity genotype score in relation to type 2 diabetes ( P for interaction=0.017). In low birth weight individuals (≤ 2.5 kg), the multivariable-adjusted odds ratio (OR) was 2.55 (95% confidence interval [CI]: 1.34–4.84) in the comparison of the highest with the lowest quartile of the obesity genotype score, while the OR was 1.27 (95%CI: 1.04–1.55) among individuals with birth weight above 2.5kg. Diabetes genotype score also showed stronger association with type 2 diabetes risk in individuals with low birth weight than those with high birth weight. Comparing individuals of the highest with the lowest quartile of the diabetes genotype score, the multivariable-adjusted odds ratio was 3.80 (95%CI: 1.76–8.24) among individuals with low birth weight and was 2.27 (95%CI: 1.82–2.83) among those with high birth weight. However, test for interaction was marginal ( P =0.16). Conclusion: Our data suggest low birth weight and genetic susceptibility to obesity may synergistically affect adulthood risk of type 2 diabetes.
An Elderly Patient With Palpitation and a Negative Nuclear Stress Test Result
Authors: Rahman Shah, M. Rehan Khan, Lee C. Holt
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Celecoxib plus carboplatin in heavily pre-treated patients with recurrent ovarian carcinoma: preliminary results of a Phase II study
Authors: G. M. Ferrandina, F. Legge, V. Gallotta, D. Lorusso, A. C. Testa, V. Salutari, A. Paglia, M. Colangelo, F. Fulfaro, G. Scambia
Journal: Journal of Clinical Oncology (2005)

5060 Background: Cyclooxygenase-2 (COX-2) expression is associated with a poor chance of response to chemotherapy and poor prognosis in ovarian cancer (OC). Celecoxib, an orally active COX-2 inhibitor, has been tested for its ability to potentiate the activity of carboplatin in treatment of heavily pretreated recurrent OC patients (pts). Methods: A phase II study with a two-stage design was planned with an early stopping in case of less than 3 responses in 13 pts. If at least four responses were observed the accrual was increased up to 43 pts with the regimen considered active if at least 12 responses were observed among 43 (α=0.05; β=0.80). Celecoxib (400 mg /die), and carboplatin (5 AUC) q28 were administered, until progression or unacceptable toxicity. Response was assessed by RECIST and Rustin criteria. Results: 18 pts (median age: 58 yrs, range 24–70; ECOG performance status 0/1/2 of 15/2/1), were enrolled. 50% of pts were platinum resistant (progressing during or < 6 months from primary treatment). Median number of previous chemotherapy regimens was 4 (range 3–6). In 18 assessed pts, 6 were just enrolled and received only the first cycle, thus leaving 12 pts evaluable for response. The overall response rate (CR and PR) was 33.3% (1 CR, 3 PR) with stabilization of disease in 3 pts (20%). Three responses occurred in platinum sensitive and 1 in platinum resistant group. Median time to response was 10 weeks (range 7–24) and median duration of response was 18 weeks (median 13–26). According to Rustin criteria 5 pts out of 11 (45.4%) achieved response to treatment with return of CA125 to normal levels in 4 patients. Given these results, the second step of enrolment is warranted. Overall, 76 cycles were administered with a median value of 8 cycles (range=1–10). Moderate/severe toxicities were as follows: G3 anemia occurred in 1.4% cycles, G3 neutropenia in 8.2% cycles, G3 thrombocytopenia in 2.6% cycles, G4 nausea/vomiting occurred in 1 case; no case of nephrotoxicity was documented. Cutaneous diffuse transient erithema was observed in 2 pts (6.3% cycles). Celecoxib combined with carboplatin is well tolerated and has promising activity as salvage treatment in heavily pretreated recurrent OC pts. No significant financial relationships to disclose.
Pathological characteristics, distant recurrence rates, and survival outcomes of breast cancer with triple-negative phenotype
Authors: C. K. Lee, E. Choo, C. R. Lewis
Journal: Journal of Clinical Oncology (2009)

e11554 Background: Breast cancer is a heterogeneous disease encompassing entities with distinct biological characteristics and clinical course. Triple-negative disease (TND) is clinically aggressive disease with limited effective therapy. We compare the clinico- pathologic characteristics, recurrence and survival rates of patients with TND and non-TND. Methods: The POWH Cancer Centre breast cancer database was retrospectively reviewed from January 1995 to December 2005. 1254 eligible women with breast cancer undergoing definitive primary breast surgery were identified. TND was defined as ER-, PR- and HER2 0 or 1+ by IHC and / or florescent in- situ hybridization (FISH) negative. Non-TND was defined as either ER+ and / or PR+ and/or HER2+. Further comparisons of survival outcomes were analyzed in a subgroup of 785 patients subdivided into three groups: ER+ and/or PR+ and HER2-, HER2+ and TND. Results: There were 135 patients (10.8%) with TND. TND tumours were characterized by larger size (p=0.02), histological grade 3 (p&lt;0.001), presence of lymphovascular invasion (p=0.03), and less likely to be diagnosed by screening mammography (p&lt;0.001) when compared with non-TND. Amongst those developing distant metastases, the median time to recurrence was 16 months for TND compared to 35 months in non-TND. There was a trend in visceral metastases for TND as compared to non-TND (OR=1.86, p=0.06). The adjusted rates for distant recurrence (HR=3.55, p=0.006), and death (HR=3.48, p=0.01) were significantly higher for TND when compared with non-TND only for first two years after diagnosis. Beyond the two years, there was no difference in distant recurrence and overall survival. Majority of the patients did not receive adjuvant anti-HER2 therapy during the study period. When compared to ER+ and/or PR+ and HER2- cohort, the survival rate was significantly poorer for TND (HR=2.66, p&lt;0.001) but non-significant for HER2+ (1.61, p=0.1). Conclusions: Poorer histopathological phenotypes are observed in TND. Patients with TND have higher rates of developing distant metastases. Survival rates are also poorer in TND patients. The risks of distant recurrence and death are not proportional across time and these risks are strongly time-dependent. No significant financial relationships to disclose.
Use of herbs and supplements by chemotherapy patients attending an integrative cancer clinic
Authors: K. I. Block, C. Gyllenhaal, A. Koch, P. Block, M. de la Torre, P. Tothy
Journal: Journal of Clinical Oncology (2008)

20712 Background: Cancer patients often seek alternative and integrative practices to supplement conventional treatment. Our clinic, The Block Center for Integrative Cancer Treatment offers cancer chemotherapy in a setting of integrative medicine, including nutrition and supplement counseling, physical care modalities (massage, yoga, fitness training) and psychological care. As a result of seeing increasing numbers of patients seeking integrative treatment, the objective of this study was to characterize this group of patients, especially with regard to intake of supplements that, if used without expert supervision, could result in potentially serious drug interactions. Methods: Data on supplement and medication use, disease type, stage, age and sex was recorded from intake questionnaires filled out by chemotherapy patients at the time of their initial visit to the Block Center before receiving counseling or treatment from the Center staff. Data was checked against intake interviews in medical records. Records of 69 cancer patients recruited from 2004 to 2007 who gave informed consent according protocol approved by the University of Illinois at Chicago IRB were included in the study. Supplements and drugs listed were evaluated for potentially negative interactions. Results: Of 69 patients, the average age was 50 years. Predominant diagnoses were breast and colon cancer (28 and 15 patients, respectively) and half (35) of the patients had stage 4 disease. 47 of the patients were female. Average number of herbs/supplements was 5.3 (range 0–29) and conventional medicines: 2.4 (range 0–11). 20 patients reported no supplement use and 20 no medications. Conclusions: While patients seeking integrative cancer treatment have a high incidence of advanced cancers and often take large numbers of supplements, no patients included in this study were determined to be at risk for major herb-drug interactions likely to cause immediate serious clinical problems. However, instances of potential problems requiring counseling were observed. Vitamins C and E, coenzyme Q10 and garlic were the most prevalent supplements taken. No significant financial relationships to disclose.
Some risk scores plus high-sensitivity troponin may identify patients with chest pain for early discharge
Authors: Eddy Lang
Journal: Annals of Internal Medicine (2016)

Source Citation Carlton EW, Khattab A, Greaves K. Identifying patients suitable for discharge after a single-presentation high-sensitivity troponin result: a comparison of five established risk scores and two high-sensitivity assays. Ann Emerg Med. 2015 Jul 29. [Epub ahead of print]. 26260100
Potential Pitfalls in the Evaluation of Ethics Consultation: The Case of Ethical Counseling
Authors: Alma Linkeviciute, Kris Dierickx, Virginia Sanchini, Giovanni Boniolo
Journal: The American Journal of Bioethics (2016)

"Potential Pitfalls in the Evaluation of Ethics Consultation: The Case of Ethical Counseling." The American Journal of Bioethics, 16(3), pp. 56–57
The Ethical Imperative of Healthy Paternalism in Advance Directive Discussions at the End of Life
Authors: David J. Einstein, Keren Ladin, Paul Mathew
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Optimal timing of surgical resection after radiation therapy in locally advanced rectal adenocarcinoma: An analysis of the National Cancer Database (NCDB).
Authors: Ciara R Huntington, Danielle Boselli, Joshua S. Hill, Jonathan C. Salo
Journal: Journal of Clinical Oncology (2015)

510 Background: In treatment of rectal adenocarcinoma, an increased time delay (TD) of 6-12 weeks from the end of radiation therapy to surgery may increase the rate of complete pathologic response (pCR), but the optimal TD with respect to survival has not been established. This study evaluates the impact of TD on overall mortality. Methods: The NCDB was queried for patients with adenocarcinoma of the rectum and no evidence of metastasis at diagnosis, who underwent preoperative chemoradiation followed by radical surgical resection. Standard statistical methods were employed for descriptive statistics and Cox model development. Results: The study included 6805 patients, predominantly Caucasian (87.2%) and males (63.9%) who generally were treated with low anterior resection (57.3%), colonanal reanastomosis (8.4%), or abdominoperineal resection (28.4%), and had median survival of 66.6 months. The effects of age, surgical margins (-/+), comorbidity index, time to discharge after surgery, TMN pathologic staging, surgical volume, and patient income significantly impacted mortality after radiation and surgery (p&lt;0.05 for all values). There was a significant relationship between TD and pCR (p=.0002). At TD less than 30 days, 4.0% of patients achieved pCR, while 9.3% of patients have achieved pCR by 75 days. In TD of greater than 75 days, the rate of pCR decreased. Overall, 6.8% of patients (n=461) achieved pCR. Using a refined cox model, a TD of more than 60 days was associated with 20% greater risk of mortality (95% CI 1.068 – 1.367). This effect became more pronounced with increasing TD; a TD of greater than 75 days was associated with 28% (95% CI 1.06-1.55) increased risk of mortality, while patients with TD less than 60 days saw a survival benefit. Conclusions: Though an interval up to 75 days between radiation and surgery may achieve higher rates of complete pathologic response, delay of more than 60 days from radiation to surgical resection and subsequent systemic chemotherapy decreases overall survival in patients with rectal cancer.
Histopathologic characteristics of scleromyxedema: A study of a series of 34 cases
Authors: Franco Rongioletti, Giulia Merlo, Carla Carli, Bernard Cribier, Dieter Metze, Eduardo Calonje, Werner Kempf, Catherine M. Stefanato, Eduardo Marinho, Jean Kanitakis
Journal: Journal of the American Academy of Dermatology (2016)
Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study
Authors: Myung-Ju Ahn, Sung Hee Lim, Jong-Mu Sun, Yoon-La Choi, Hye Ryun Kim, Soo-min Ahn, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Joo Hang Kim, Byoung Chul Cho
Journal: Journal of Thoracic Oncology (2016)
Phase I study to evaluate the safety and efficacy of MEDI4736 in combination with tremelimumab in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Authors: Lillian L. Siu, Kyriakos P. Papadopoulos, Frank Yung-Chin Tsai, Aaron Richard Hansen, Paul B. Robbins, Xia Li, Dominic W Lai, John A. Blake-Haskins, Matthew G. Fury
Journal: Journal of Clinical Oncology (2015)

TPS3090 Background: Despite advances in the treatment of SCCHN, the outlook for patients (pts) with R/M disease remains poor. Development of immunotherapies to treat this disease may hold promise. High mutational burden due to tobacco and expression of human papilloma virus (HPV)-associated viral antigens is linked to immunogenicity in SCCHN tumors. Despite this immunogenicity, tumors can evade immune detection by exploiting inhibitory checkpoints. PD-L1 is up-regulated on SCCHN tumors and is associated with antitumor T-cell response inhibition. MEDI4736 (M), a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80 with high affinity and selectivity, has shown a manageable safety profile and promising antitumor activity in R/M SCCHN (ORR 24% in PD-L1+ pts, phase I)(Fury M, et al. Poster presented at ESMO 2014, 988PD). Tremelimumab (T), a selective human IgG2 mAb inhibitor of CTLA-4, has also shown antitumor activity in several tumor types (Tarhini AA. Immunotherapy 2013;5:215–29). Preclinical data suggest that combining anti-PD-L1 and anti-CTLA-4 provides non-redundant immune checkpoint blockade and synergistic antitumor activity. Preliminary data for M + T in NSCLC show encouraging clinical activity in both PD-L1-positive and PD-L1-negative pts (Antonia S, et al. Poster presented at ESMO 2014, 1327P). Here we describe a study assessing the safety, efficacy, and potential biomarkers of response to M + T, in pts with R/M SCCHN. Methods: This is a phase I, multicenter, open-label study (NCT02262741) in pts (N~164) with R/M SCCHN deemed incurable by local therapy. The dose exploration phase will evaluate the combination of M + T, followed by dose expansion in treatment-naive or pretreated R/M pts. Pts will have PD-L1 status determined prior to dosing with M IV + T IV or T IV alone. The primary objective is to assess safety/tolerability of M + T and T alone. Secondary objectives are to assess antitumor activity via RECIST (including ORR, DCR, DoR, PFS, and OS), PK/PD, immunogenicity, and if clinical activity correlates with potential biomarkers, including PD-L1 expression, HPV status, and tobacco use. Recruitment is ongoing. Clinical trial information: NCT02262741.
In Vitro Peripheral Monocyte Culture: Possible Use as a Prognostic Indicator for Renal Cell Carcinoma Patients
Authors: E C Krishnan, W K Mebust, J W Weigel, W R Jewell
Journal: JNCI Journal of the National Cancer Institute (1985)

An in vitro assay was applied to follow 39 patients with renal cell carcinoma. A mononuclear cell-rich fraction was cultured from peripheral blood of patients over a period of 7 days. The number of adherent matured monocytes (macrophages) was analyzed and quantitated at the end of the culture period. Functional activities were analyzed by antibody-coated sheep red blood cells and nonspecific esterase staining techniques. Macrophage yield in patients with detectable tumor burden was 2.06 +/- 2.81 X 10(4) cells/ml blood, and mean values at 3, 6, and 9 months post nephrectomy were 3.67 (n = 21), 6.73 (n = 12), and 9.41 (n = 10) X 10(4) cells/ml blood, respectively. Some of the patients were followed over 30 months. The improvement was significant, and macrophage yield was close to normal values (8.24 +/- 3.14 X 10(4) cells/ml). In the absence of other reliable in vitro assays for these patients, this assay appears to be highly useful in following these patients during the postsurgical period.